• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/11/21 3:10:40 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PTE alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2(b)

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 6)*

     

    POLARITYTE, INC.

     

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    731094108

     

    (CUSIP Number)

     

    December 31, 2020

     

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the Rule pursuant to which this Schedule is filed:

     

      [  ] Rule 13d – 1(b)
      [X] Rule 13d – 1(c)
      [  ] Rule 13d – 1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 731094108
      1. NAME OF REPORTING PERSON OR
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    Barry Honig
         
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) [  ]
        (b) [  ]
         
      3. SEC USE ONLY
         
      4. CITIZENSHIP OR PLACE OF ORGANIZATION
    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
    0
       
    6. SHARED VOTING POWER
    787,314
       
    7. SOLE DISPOSITIVE POWER
    0
       
    8. SHARED DISPOSITIVE POWER
    787,314

     

      9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    787,314 (1)
         
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [  ]
         
      11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.31% (based on 60,132,822 shares outstanding as of January 8, 2021)

         
      12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    IN

     

    (1)

    Includes (i) 393,054 shares of common stock held by GRQ Consultants, Inc. Roth 401K FBO Barry Honig (“Roth 401K”), (ii) 344,952 shares of common stock held by GRQ Consultants, Inc. 401K (“401K”), and (iii) 49,308 shares of common stock held by GRQ Consultants, Inc. Roth 401K FBO Renee Honig (“Renee 401K”).

       
     

    Barry Honig’s father, Alan S. Honig (“Alan Honig”), and Barry Honig’s wife, Renee Honig (“Renee Honig”), are co-trustees of each of 401K, Roth 401K and Renee 401K. By virtue of his current relationship with his father with regard to the shares of common stock held by 401K, Roth 401K and Renee 410K, and the spousal relationship with his wife with regard to the shares of common stock held by 401K, Roth 401K and Renee 401K, Barry Honig may have influence on all of the shares of common stock held by each of 401K, Roth 401K and Renee 401K, and may be deemed, directly or indirectly, to have beneficial ownership of all such shares of common stock.

     

     -2- 
     

     

    CUSIP No. 731094108
      1. NAME OF REPORTING PERSON OR
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    Renee Noel Honig
         
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) [  ]
        (b) [  ]
         
      3. SEC USE ONLY
         
      4. CITIZENSHIP OR PLACE OF ORGANIZATION
    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
    0
       
    6. SHARED VOTING POWER

    787,314

       
    7. SOLE DISPOSITIVE POWER
    0
       
    8. SHARED DISPOSITIVE POWER

    787,314

     

      9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    787,314 (1)

         
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [  ]
         
      11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.31% (based on 60,132,822 shares outstanding as of January 8, 2021)

         
      12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    IN

     

    (1)

    Includes (i) 393,054 shares of common stock held by Roth 401K, (ii) 344,952 shares of common stock held by 401K, and (iii) 49,308 shares of common stock held by Renee 401K.

       
     

    Renee Honig is co-trustee of each of 401K, Roth 401K and Renee 401K and in such capacity holds voting and dispositive power over the securities held by each of 401K, Roth 401K and Renee 401K.

     

     -3- 
     

     

    CUSIP No. 731094108
      1. NAME OF REPORTING PERSON OR
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    Alan S. Honig
         
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) [  ]
        (b) [  ]
         
      3. SEC USE ONLY
         
      4. CITIZENSHIP OR PLACE OF ORGANIZATION
    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
    0
       
    6. SHARED VOTING POWER

    915,114

       
    7. SOLE DISPOSITIVE POWER
    0
       
    8. SHARED DISPOSITIVE POWER

    915,114

     

      9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    915,114 (1)

         
      10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    [  ]

         
      11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.52% (based on 60,132,822 shares outstanding as of January 8, 2021)

         
      12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    IN

     

    (1)

    Includes (i) 393,054 shares of common stock held by Roth 401K, (ii) 344,952 shares of common stock held by 401K, (iii) 49,308 shares of common stock held by Renee 401K, and (iv) 127,800 shares of common stock held by Barry & Renee Honig Charitable Foundation, Inc. (“Foundation”).

       
     

    Alan Honig is co-trustee of each of 401K, Roth 401K and Renee 401K and in such capacity holds voting and dispositive power over the securities held by each of 401K, Roth 401K and Renee 401K. Alan Honig is President of the Foundation and in such capacity holds voting and dispositive power over the securities held by the Foundation.

     

     -4- 
     

     

    CUSIP No. 731094108
      1. NAME OF REPORTING PERSON OR
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    Barry & Renee Honig Charitable Foundation Inc.
         
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) [  ]
        (b) [  ]
         
      3. SEC USE ONLY
         
      4. CITIZENSHIP OR PLACE OF ORGANIZATION
    Florida

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
    0
       
    6. SHARED VOTING POWER
    127,800 (1)
       
    7. SOLE DISPOSITIVE POWER
    0
       
    8. SHARED DISPOSITIVE POWER
    127,800 (1)

     

      9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    127,800 (1)
         
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [  ]
         
      11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.21% (based on 60,132,822 shares outstanding as of January 8, 2021)

         
      12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    CO

     

    (1)

    Alan Honig is the president of the Foundation and in such capacity holds voting and dispositive power over the securities held by the Foundation.

     

     -5- 
     

     

    CUSIP No. 731094108
      1. NAME OF REPORTING PERSON OR
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    GRQ Consultants, Inc. Roth 401K FBO Barry Honig
         
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) [  ]
        (b) [  ]
         
      3. SEC USE ONLY
         
      4. CITIZENSHIP OR PLACE OF ORGANIZATION
    Florida

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
    0
       
    6. SHARED VOTING POWER
    393,054 (1)
       
    7. SOLE DISPOSITIVE POWER
    0
       
    8. SHARED DISPOSITIVE POWER
    393,054 (1)

     

      9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    393,054 (1)
         
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [  ]
         
      11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.65% (based on 60,132,822 shares outstanding as of January 8, 2021)

         
      12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    OO

     

    (1)

    Alan Honig and Renee Honig are co-trustees of Roth 401K and in such capacity are each deemed to hold voting and dispositive power over the securities held by such entity.

     

     -6- 
     

     

    CUSIP No. 731094108
      1. NAME OF REPORTING PERSON OR
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    GRQ Consultants, Inc. 401K
         
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) [  ]
        (b) [  ]
         
      3. SEC USE ONLY
         
      4. CITIZENSHIP OR PLACE OF ORGANIZATION
    Florida

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
    0
       
    6. SHARED VOTING POWER
    344,952 (1)
       
    7. SOLE DISPOSITIVE POWER
    0
       
    8. SHARED DISPOSITIVE POWER
    344,952 (1)

     

      9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    344,952 (1)
         
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [  ]
         
      11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.57% (based on 60,132,822 shares outstanding as of January 8, 2021)

         
      12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    OO

     

    (1)

    Alan Honig and Renee Honig are co-trustees of Roth 401K and in such capacity are each deemed to hold voting and dispositive power over the securities held by such entity.

     

     -7- 
     

     

    CUSIP No. 731094108
      1. NAME OF REPORTING PERSON OR
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    GRQ Consultants, Inc. Roth 401K FBO Renee Honig
         
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) [  ]
        (b) [  ]
         
      3. SEC USE ONLY
         
      4. CITIZENSHIP OR PLACE OF ORGANIZATION
    Florida

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
    0
       
    6. SHARED VOTING POWER
    49,308 (1)
       
    7. SOLE DISPOSITIVE POWER
    0
       
    8. SHARED DISPOSITIVE POWER
    49,308 (1)

     

      9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    49,308 (1)
         
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [  ]
         
      11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.08% (based on 60,132,822 shares outstanding as of January 8, 2021)

         
      12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    OO

     

    (1)

    Alan Honig and Renee Honig are co-trustees of Roth 401K and in such capacity are each deemed to hold voting and dispositive power over the securities held by such entity.

     

     -8- 
     

     

    Item 1(a). Name of Issuer:
       
      PolarityTE, Inc., a Delaware corporation (“Issuer”).
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      123 Wright Brothers Drive, Salt Lake City, Utah 84116
       
    Item 2(a). Name of Person Filing.
       
     

    The statement is filed on behalf of Barry Honig, Renee Noel Honig (“Renee Honig”), Alan S. Honig (“Alan Honig”), Barry & Renee Honig Charitable Foundation, Inc. (the “Foundation”), GRQ Consultants, Inc. 401K (“401K”), GRQ Consultants, Inc. Roth 401K FBO Barry Honig (“Roth 401K”) and GRQ Consultants, Inc. Roth 401K FBO Renee Honig (“Renee 401K”) (collectively, the “Reporting Persons”).

       
     

    Alan Honig is president of the Foundation and in such capacity has voting and dispositive power over the securities held by such entity. Alan Honig and Renee Honig are co-trustees of each of 401K, Roth 401K and Renee 401K and in such capacity each has voting and dispositive power over the securities held by each such entity.

       
     

    By virtue of his current relationship with his father with regard to the shares of common stock held by 401K, Roth 401K, and Renee 410K, and the spousal relationship with his wife with regard to the shares of common stock held by 401K, Roth 401K, and Renee 401K, Barry Honig may have influence on all of the shares of common stock held by each of 401K, Roth 401K, and Renee 401K, and may be deemed, directly or indirectly, to have beneficial ownership of all of such shares of common stock.

       
    Item 2(b). Address of Principal Business Office or, if None, Residence.
       
      215 SE Spanish Trail, Boca Raton, FL 33432
       
    Item 2(c). Citizenship.
       
     

    Barry Honig, Renee Honig and Alan Honig are each citizens of the United States. The Foundation, 401K, Roth 401K, and Renee 401K, are each organized in the state of Florida.

       
    Item 2(d). Title of Class of Securities.
       
      Common Stock, par value $0.001.
       
    Item 2(e). CUSIP Number.
       
      731094108
       
    Item 3. Type of Person.
       
      Not applicable.

     

     -9- 
     

     

    Item 4. Ownership.
       
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each of the Reporting Persons hereto, including footnotes, and is incorporated herein by reference for the Reporting Persons. The percentage set forth in Row (11) of the cover page for each of the Reporting Persons is based on a total of 60,132,822 shares of common stock of the Issuer as of January 8, 2021, as disclosed on the Issuer’s Prospectus Supplement filed pursuant to 424(b)(5) (to the Prospectus dated February 22, 2019) filed with the Securities and Exchange Commission on January 26, 2021. The information set forth in Rows (5) – (11) of the cover page for each of the Reporting Persons hereto is made as of December 31, 2020.

       
    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
      Not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company.
       
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.
       
    Item 9. Notice of Dissolution of Group.
       
      Not applicable.
       
    Item 10. Certifications.
       
     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     -10- 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 11, 2021
      Date
       
      BARRY HONIG
       
      /s/ Barry Honig
      Signature
       
      RENEE NOEL HONIG
       
      /s/ Renee Noel Honig
      Signature
       
      ALAN S. HONIG
       
      /s/ Alan S. Honig
      Signature
       
      BARRY & RENEE HONIG CHARITABLE FOUNDATION, INC.
       
      /s/ Alan S. Honig
      Signature
       
      Alan S. Honig, President
      Name/Title
       
      GRQ CONSULTANTS, INC. ROTH 401K FBO BARRY HONIG
       
      /s/Renee Noel Honig
      Signature
       
      Renee Noel Honig, Co-Trustee
      Name/Title
       
      /s/ Alan S. Honig
      Signature
       
      Alan S. Honig, Co-Trustee
      Name/Title

     

     -11- 
     

     

      GRQ CONSULTANTS, INC. ROTH 401K FBO RENEE HONIG
       
      /s/ Renee Noel Honig
      Signature
       
      Renee Noel Honig, Co-Trustee
      Name/Title
       
      /s/ Alan S. Honig
      Signature
       
      Alan S. Honig, Co-Trustee
      Name/Title
       
      GRQ CONSULTANTS, INC. 401K
       
      /s/ Renee Noel Honig
      Signature
       
      Renee Noel Honig, Co-Trustee
      Name/Title
       
      /s/ Alan S. Honig
      Signature
       
      Alan S. Honig, Co-Trustee
      Name/Title

     

     -12- 

    Get the next $PTE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PTE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PTE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company

      SALT LAKE CITY, Dec. 27, 2022 /PRNewswire/ --  PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials (the "Company"), today announced that it signed a non-binding letter of intent (the "LOI") with Michael Brauser ("Brauser") for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash. As of December 23, 2022, there were 7,256,786 shares of the Company's common stock outstanding and unvested restricted stock units covering an additional 256,457 common shares. 

      12/27/22 8:30:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update

      SALT LAKE CITY, Nov. 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022. Recent Business and Financial UpdatesAt the end of April 2022, PolarityTE began enrollment in its Phase III randomized controlled trial (RCT), which is a pivotal study under its open IND for SkinTE®. The Company estimates that it may be able to complete enrollment of 100 subjects sometime in the first six mon

      11/10/22 4:30:00 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company

      SALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash. The offer is subject to various contingencies, including, among others, (1) settlement with warrant holders and satisfactory negotiations with insiders with change of control agreements, (2) minimum tender conditions, (3) a sixty-day due diligence period, and (4) satisfacti

      11/9/22 8:00:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Dyer Jeffrey Hansen was granted 42,986 shares, increasing direct ownership by 3,177% to 44,339 units

      4 - POLARITYTE, INC. (0001076682) (Issuer)

      1/30/23 4:30:42 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3: New insider Dyer Jeffrey Hansen claimed ownership of 1,353 shares

      3 - POLARITYTE, INC. (0001076682) (Issuer)

      1/30/23 4:15:33 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Nolet Chris decreased direct ownership by 72% to 14,403 units

      4 - POLARITYTE, INC. (0001076682) (Issuer)

      1/17/23 4:30:29 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    Financials

    Live finance-specific insights

    See more
    • PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update

      PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET SALT LAKE CITY, Aug. 11, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended June 30, 2022. Recent Business and Financial UpdatesIn January 2022, PolarityTE was advised by the U.S. Food and Drug Administration (FDA) that it could conduct human clinical trials under PolarityTE's investigational new drug application (IND

      8/11/22 4:05:00 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE to Report Q2 2022 Financial Results on August 11, 2022

      SALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on August 11, 2022, at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-800-207-0148 with passcode 893469 and referencing "PolarityTE Second Quarter 2022 Business Update and Financial Results." A webcast of the conference call can be accesse

      8/1/22 8:00:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Polarity TE spins off IBEX Preclinical Research contract research organization

      Dr. Josh Packer acquires IBEX and becomes CEO; maintains existing surgical research team LOGAN, Utah, May 26, 2022 /PRNewswire-PRWeb/ -- IBEX Preclinical Research, Inc., a trusted outsourcing partner and provider of preclinical surgical and toxicological studies in a variety of laboratory animal species, announced that it has been acquired by Josh Packer, DVM. IBEX provides in-vivo research services ranging from relatively simple single-dose pharmacokinetic studies to more complex projects requiring surgical instrumentation. Conducting both GLP and non-GLP non-clinical testing, IBEX supports life science, medical device companies and researchers that specialize in orthopedics, neurosurgical,

      5/26/22 11:15:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    SEC Filings

    See more
    • PolarityTE Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - POLARITYTE, INC. (0001076682) (Filer)

      8/18/23 4:54:40 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form NT 10-Q filed by PolarityTE Inc.

      NT 10-Q - POLARITYTE, INC. (0001076682) (Filer)

      8/15/23 4:40:32 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

      8-K - POLARITYTE, INC. (0001076682) (Filer)

      8/15/23 4:30:36 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    Leadership Updates

    Live Leadership Updates

    See more
    • PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors

      SALT LAKE CITY, Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately. "On behalf of our Board and PolarityTE's management team, we thank Jeff for his service and longstanding commitment to the Company," stated Richard Hague, Chief Executive Officer of PolarityTE.  "We greatly appreciate the leadership and insight that Jeff has provided over the past five and a half years as we purs

      9/8/22 8:30:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

      2/23/21 4:05:00 PM ET
      $VIE
      $PTE
      $RVNC
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: Pharmaceutical Preparations

    $PTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by PolarityTE Inc. (Amendment)

      SC 13G/A - POLARITYTE, INC. (0001076682) (Subject)

      2/14/23 11:11:43 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by PolarityTE Inc.

      SC 13G - POLARITYTE, INC. (0001076682) (Subject)

      8/23/22 11:30:24 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed

      SC 13G - POLARITYTE, INC. (0001076682) (Subject)

      2/16/21 5:19:31 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care